keyword
MENU ▼
Read by QxMD icon Read
search

Vaginal atrophy

keyword
https://www.readbyqxmd.com/read/28202320/the-women-s-empower-survey-identifying-women-s-perceptions-on-vulvar-and-vaginal-atrophy-and-its-treatment
#1
Sheryl A Kingsberg, Michael Krychman, Shelli Graham, Brian Bernick, Sebastian Mirkin
INTRODUCTION: Vulvar and vaginal atrophy (VVA) affects up to two thirds of postmenopausal women, but most symptomatic women do not receive prescription therapy. AIM: To evaluate postmenopausal women's perceptions of VVA and treatment options for symptoms in the Women's EMPOWER survey. METHODS: The Rose Research firm conducted an internet survey of female consumers provided by Lightspeed Global Market Insite. Women at least 45 years of age who reported symptoms of VVA and residing in the United States were recruited...
February 12, 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28202319/the-women-s-empower-survey-women-s-knowledge-and-awareness-of-treatment-options-for-vulvar-and-vaginal-atrophy-remains-inadequate
#2
Michael Krychman, Shelli Graham, Brian Bernick, Sebastian Mirkin, Sheryl A Kingsberg
INTRODUCTION: Postmenopausal women's knowledge about vulvar and vaginal atrophy (VVA) and available treatment options has historically been inadequate. Recent direct-to-consumer marketing and educational efforts would have been expected to increase awareness and treatment options. AIM: To compare results of the Women's EMPOWER survey with other available VVA surveys to assess progress in women's understanding and approaches to treatment of VVA. METHODS: The Women's EMPOWER survey, an internet-based survey of US women with VVA symptoms, assessed women's awareness of VVA and their behaviors and attitudes associated with symptom treatment...
February 12, 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28195995/patient-acceptability-and-satisfaction-with-a-low-dose-solubilized-vaginal-estradiol-softgel-capsule-tx-004hr
#3
Sheryl A Kingsberg, Robin Kroll, Irwin Goldstein, Harvey Kushner, Brian Bernick, Shelli Graham, Sebastian Mirkin, Ginger D Constantine
OBJECTIVE: TX-004HR is an investigational, muco-adhesive, vaginal, softgel capsule containing low-dose, solubilized, 17β-estradiol designed to treat postmenopausal vulvar and vaginal atrophy (VVA) and improve user experience without an applicator and less mess. METHODS: As part of the 12-week, placebo-controlled, double-blind, phase 3 REJOICE trial evaluating the efficacy/safety of 4-, 10-, and 25-μg TX-004HR in 764 postmenopausal women with VVA, a five-question product survey was administered...
February 13, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28070251/comparison-between-vaginal-royal-jelly-and-vaginal-estrogen-effects-on-quality-of-life-and-vaginal-atrophy-in-postmenopausal-women-a-clinical-trial-study
#4
Fatemeh Seyyedi, Mahmoud Rafiean Kopaei, Sepideh Miraj
OBJECTIVE: This study was conducted to evaluate the therapeutic effects of vaginal royal jelly and vaginal estrogen on quality of life and vaginal atrophy in postmenopausal women. METHODS: This double-blind randomized controlled clinical trial was carried out at gynecology and obstetrics clinics of Hajar Hospital of Shahrekord University of Medical Sciences (Iran) from January 2013 to January 2014. The study was conducted on married postmenopausal women between 50 and 65 years old...
November 2016: Electronic Physician
https://www.readbyqxmd.com/read/28056209/fractional-co2-laser-from-skin-rejuvenation-to-vulvo-vaginal-reshaping
#5
Maurizio Filippini, Ester Del Duca, Francesca Negosanti, Diletta Bonciani, Luca Negosanti, Mario Sannino, Giovanni Cannarozzo, Steven Paul Nisticò
BACKGROUND: The CO2 laser has become the gold standard treatment in dermatologic surgery for the treatment of a large number of skin and mucosal lesions. The introduction of the fractional micro-ablative technology represented an integration to the ablative resurfacing technique, reducing the healing time and the side effects. OBJECTIVE: Vaginal rejuvenation performed with this technique is a minimally invasive procedure that stimulates internal tissues of the female lower genital tract to regenerate the mucosa, improving tissue trophism and restoring the correct functionality...
December 30, 2016: Photomedicine and Laser Surgery
https://www.readbyqxmd.com/read/28042734/vulvar-and-vaginal-atrophy-as-viewed-by-the-spanish-revive-participants-symptoms-management-and-treatment-perceptions
#6
S Palacios, M J Cancelo, C Castelo Branco, P Llaneza, F Molero, R Sanchez Borrego
OBJECTIVES: To gain a deeper comprehension of current vulvovaginal atrophy (VVA) knowledge among Spanish postmenopausal women. METHODS: An online survey (REVIVE) was conducted in four European countries with an overall sample of 768 participants included in Spain. Perceptions, experiences and needs of Spanish postmenopausal women in terms of sexual and vaginal health were reported. RESULTS: Vaginal dryness was the most common VVA symptom in Spain (81%)...
February 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28042713/clarifying-vaginal-atrophy-s-impact-on-sex-and-relationships-closer-survey-in-south-africa
#7
F Guidozzi, C Thomas, T Smith, R E Nappi
OBJECTIVE: With a paucity of information from sub-Saharan Africa, the impact of postmenopausal vaginal atrophy on women and male partners in South Africa was investigated. METHODS: Four hundred individuals in South Africa (200 postmenopausal women who had experienced symptoms of vaginal atrophy, and 200 male partners) completed a structured questionnaire. RESULTS: Sixty-eight percent of women had avoided intimacy because of vaginal discomfort; 62% of men described observing this behavior in their partners...
February 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28042397/treatment-of-vaginal-atrophy-with-vaginal-estrogen-cream-in-menopausal-indian-women
#8
Maitri Shah, Zalak Karena, Sangita V Patel, Niyati Parmar, Pawan K Singh, Atul Sharma
OBJECTIVES: To measure the effect of vaginal estrogen cream in the treatment of vaginal atrophy in menopausal Indian women. METHODS: A total of 50 menopausal women aged between 40 and 80 years old with symptoms of vaginal atrophy were selected and treated with 0.5 g vaginal estrogen cream, twice weekly for 12 weeks. The women were followed-up monthly where symptom score, Genital Health Clinical Evaluation (GHCE) score, vaginal pH, and vaginal maturation index (VMI) were assessed and compared to baseline data...
January 2017: Oman Medical Journal
https://www.readbyqxmd.com/read/28002201/tx-004hr-vaginal-estradiol-has-negligible-to-very-low-systemic-absorption-of-estradiol
#9
David F Archer, Ginger D Constantine, James A Simon, Harvey Kushner, Philip Mayer, Brian Bernick, Shelli Graham, Sebastian Mirkin
OBJECTIVE: To evaluate the pharmacokinetics of TX-004HR vaginal estradiol softgel capsules when used for treating moderate-to-severe dyspareunia in postmenopausal women with vulvar and vaginal atrophy. METHODS: A substudy of the REJOICE trial (multicenter, double-blind, placebo-controlled, phase 3) evaluated the pharmacokinetics of 4, 10, and 25-μg TX-004HR doses once/d for 2 weeks, followed by twice/wk for 10 weeks. Serum samples obtained at 2, 4, 6, 10, and 24 hours postdose on days 1 and 14, and once on day 84, were analyzed for area under the serum concentration-time curve, tmax, Cmin, Cavg, and Cmax for estradiol, estrone, and estrone conjugates...
December 19, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27973466/treatment-of-menopausal-symptoms-new-era-with-new-options-or-new-options-for-menopausal-symptoms-after-15-years-of-whi-study
#10
Santiago Palacios, Pluvio J Coronado
Menopausal symptoms include vasomotor symptoms (VMS), vulvar-vaginal atrophy, and loss of bone mass associated with an increased risk of fracture. Treatment of VMS consists of lifestyle changes, hormone treatment (estrogens with and without progestogens, tissue selective estrogens complex or conjugated estrogens and bazedoxifene [CE/BZA], progestogens, and tibolone), and nonhormonal treatments. Genitourinary symptoms due to vulvar-vaginal atrophy are treated with systemic and local hormones, moisturizer creams and gels, CE/BZA, and a selective estrogen receptor modulator (ospemifene)...
December 14, 2016: Minerva Ginecologica
https://www.readbyqxmd.com/read/27929271/hormone-therapy-and-other-treatments-for-symptoms-of-menopause
#11
D Ashley Hill, Mark Crider, Susan R Hill
The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. In the past, physicians prescribed hormone therapy to improve overall health and prevent cardiac disease, as well as for symptoms of menopause. Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years. Therefore, in women with a uterus, it is recommended that physicians prescribe combination therapy only to treat menopausal symptoms such as vasomotor symptoms (hot flashes) and vaginal atrophy, using the smallest effective dosage for the shortest possible duration...
December 1, 2016: American Family Physician
https://www.readbyqxmd.com/read/27922936/the-rejoice-trial-a-phase-3-randomized-controlled-trial-evaluating-the-safety-and-efficacy-of-a-novel-vaginal-estradiol-soft-gel-capsule-for-symptomatic-vulvar-and-vaginal-atrophy
#12
Ginger D Constantine, James A Simon, James H Pickar, David F Archer, Harvey Kushner, Brian Bernick, Gina Gasper, Shelli Graham, Sebastian Mirkin
OBJECTIVE: To evaluate the safety and efficacy of TX-004HR vaginal estradiol soft-gel capsules for moderate-to-severe dyspareunia associated with postmenopausal vulvar and vaginal atrophy. METHODS: In this randomized, double-blind, placebo-controlled, phase 3 study, postmenopausal women with a self-identified most bothersome symptom of dyspareunia received 4, 10, or 25 μg TX-004HR or placebo for 12 weeks. Four co-primary efficacy endpoints were change from baseline to week 12 in percentages of superficial and parabasal cells, vaginal pH, and severity of dyspareunia...
December 5, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27914565/response-and-rebuttal-to-editorial-comment-on-tx-004hr-improves-sexual-function-as-measured-by-the-female-sexual-function-index-in%C3%A2-postmenopausal-women-with-vulvar-and-vaginal-atrophy-the%C3%A2-rejoice%C3%A2-trial
#13
Sheryl A Kingsberg, Leonard Derogatis, James A Simon, Ginger D Constantine, Shelli Graham, Brian Bernick, Gina Gasper, Sebastian Mirkin
No abstract text is available yet for this article.
December 2016: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/27914564/editorial-comment-on-tx-004hr-improves-sexual-function-as-measured-by-the-female-sexual-function-index-in-postmenopausal-women-with-vulvar-and-vaginal-atrophy-the-rejoice-trial
#14
https://www.readbyqxmd.com/read/27904630/a-survey-of-the-therapeutic-effects-of-vitamin-e-suppositories-on-vaginal-atrophy-in-postmenopausal-women
#15
Aazam Parnan Emamverdikhan, Nahid Golmakani, Sayyed ASajadi Tabassi, Malihe Hassanzadeh, Nooriyeh Sharifi, Mohammad Taghi Shakeri
BACKGROUND: Menopause is associated with various complications such as depression, sleep disorders, and genitourinary atrophy. Vaginal atrophy occurs due to the loss of steroid hormones, and its major symptoms include vaginal dryness, itching, dyspareunia, and bleeding after intercourse. According to the literature, vitamin E plays a key role in estrogen stability. The aim of this study was to compare the effects of vitamin E suppositories and conjugated estrogen vaginal cream on vaginal atrophy...
September 2016: Iranian Journal of Nursing and Midwifery Research
https://www.readbyqxmd.com/read/27896230/evaluation-of-symptoms-and-prevention-of-cancer-in-menopause-the-value-of-vulvar-exam
#16
A R Palumbo, C Fasolino, G Santoro, V Gargano, M Rinaldi, B Arduino, M Belli, M Guida
Vulvar and vaginal atrophy (VVA), is a chronic medical condition experienced by postmenopausal women, with prevalence estimated ranging from 10% to 50% [1]. VVA is characterized by a constellation of symptoms, that may affect daily activities, sexuality, relationships, and quality of life [3]. Early recognition and effective treatment of VVA may enhance sexual health and the quality of life of women and their partners. Some vulvar conditions such as lichen sclerosus are more prevalent in the postmenopausal years...
November 2016: Translational Medicine @ UniSa
https://www.readbyqxmd.com/read/27875388/is-vulvovaginal-atrophy-due-to-a-lack-of-both-estrogens-and-androgens
#17
Fernand Labrie, Céline Martel, Georges Pelletier
OBJECTIVE: The aim of this study was to review the preclinical data showing the role of both estrogens and androgens in the physiology of the vagina, and, most likely, in vulvovaginal atrophy of menopause. METHODS: Mass spectrometry-based assays (validated according to the FDA guidelines) for the measurement of sex steroids, their precursors, and metabolites were used. In addition to fixation of the vagina for morphological examination, histomorphometry, immunocytochemistry, immunofluorescence, and quantitative reverse transcription polymerase chain reaction were performed...
November 21, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27832260/vaginal-testosterone-cream-vs-estradiol-vaginal-ring-for-vaginal-dryness-or-decreased-libido-in-women-receiving-aromatase-inhibitors-for-early-stage-breast-cancer-a-randomized-clinical-trial
#18
Michelle E Melisko, Mindy E Goldman, Jimmy Hwang, Amy De Luca, Sally Fang, Laura J Esserman, Amy J Chien, John W Park, Hope S Rugo
Importance: Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. Objective: To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI. Intervention was considered unsafe if more than 25% of patients had persistent elevation in estradiol (E2), defined as E2 greater than 10 pg/mL (to convert to pmol/L, multiply by 3...
November 10, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27831658/postmenopausal-vulvovaginal-atrophy-vva-is-positively-improved-by-topical-hyaluronic-acid-application-a-prospective-observational-study
#19
M Origoni, C Cimmino, G Carminati, E Iachini, C Stefani, S Girardelli, S Salvatore, M Candiani
OBJECTIVE: To evaluate the effectiveness of a topical vaginal preparation containing hyaluronic acid in controlling signs and symptoms correlated with postmenopausal vulvovaginal atrophy (VVA). PATIENTS AND METHODS: A prospective, observational study has been performed at the Obstetrics and Gynecology Department of the Vita Salute San Raffaele University of Milan, Italy. Forty-six (46) consecutive postmenopausal women complaining of genital discomfort due to postmenopausal estrogen lack have been enrolled...
October 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27830882/histological-changes-in-the-vulva-and-vagina-from-ovariectomised-rats-undergoing-oestrogen-treatment
#20
R F Mocan-Hognogi, N Costin, A Malutan, R Ciortea, I A Trif, A L Nagy, M L Bogdan, D Mihu
BACKGROUND: The purpose of this study was to assess the histological changes occurring in the vagina and vulva in ovariectomised female rats, as well as the response to the administration of injectable oestrogens. MATERIAL AND METHODS: We used 30 female Wistar white rats, distributed as follows: group 1 - the control group, group 2 - the operated but untreated rats, and groups 3, 4 and 5 - operated rats, to which oestrogenic treatment was administered (Estradiol, Estradurin, Sintofolin) at a dosage of 0...
2016: Folia Morphologica (Warsz)
keyword
keyword
19676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"